, Volume 44, Issue 2, pp 142–145 | Cite as

Human platelet 5-hydroxytryptamine receptors: Binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration

  • D. G. Grahame-Smith
  • D. P. Geaney
  • M. Schachter
  • J. M. Elliott
Multi-author Review The Platelet in Pathophysiological Research


Chronic treatment with phenothiazines and thioxanthenes has been found to enhance 5-HT-induced aggregation of human platelets. A method has been developed to study 5-HT2 receptor binding sites on platelets utilising [3H]-LSD and more recently125I/LSD. Results are presented which suggest that the LSD binding site is indeed the 5-HT2 binding site and that the LSD binding characterises the specific receptor responsible for 5-HT-induced shape change and aggregation.

In a group of patients receiving phenothiazines or thioxanthenes, theBmax of LSD binding was increased. The mean binding affinity was decreased possibly due to a persistence of neuroleptic in the platelet membrane preparation. Analysis showed that this was not the reason why the mean binding capacity was increased.

The results show that chronic phenothiazine and thioxanthene δ treatment ‘up-regulates’ platelet 5-HT2 binding sites and that this may be accompanied by increased sensitivity to platelet aggregation by 5-HT.

In normal subjects desipramine treatment increased theBmax of platelet LSD binding and this was accompanied by an increased prolactin response to tryptophan which is thought to be mediated by central 5-HT function.

Key words

Platelets 5-HT LSD binding neuroleptics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson, I. M., and Cowen, P. J., Clomipramine enhances prolactin and growth hormone responses tol-tryptophan. Psychopharmacology89 (1986) 131–133.PubMedGoogle Scholar
  2. 2.
    Bennet, J. P., and Snyder, S. H., Stereospecific binding ofd-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res.94 (1975) 523.PubMedGoogle Scholar
  3. 3.
    Baldacci, M., Bergel, T. D., Born, G. V. R., and Hickman, M., Increases in aggregation by uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine. Br. J. Pharmac. Chemother.69 (1980) 113–118.Google Scholar
  4. 4.
    Boullin, D. J., Grahame-Smith, D. G., Grimes, R. P. J., and Woods, H. F., Inhibition of hydroxytryptamine induced human blood platelet aggregation by chlorpromazine and its metabolites. Br. J. Pharmac. Chemother.53 (1975) 121–125.Google Scholar
  5. 5.
    Boullin, D. J., Woods, H. F., Grimes, R. P. J., Grahame-Smith, D. G., Wiles, D., Gelder, M. G., and Kolakowska, T., Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br. J. clin. Pharmac.2 (1975) 29–35.Google Scholar
  6. 6.
    Boullin, D. J., Orr, M. W., and Peters, J. R., The platelet as a model for investigating clinical efficacy of centrally acting drugs: relations between platelet aggregation and clinical condition in schizophrenics treated with chlorpromazine, in: Platelets: a Multi-disciplinary Approach. Eds S. E. de Gaetano and S. Gorathine. Raven Press, New York 1978.Google Scholar
  7. 7.
    Boullin, D. J., Knox, J. M., Peters, J., and Orr, M., Platelet aggregation and chlorpromazine therapy. Br. J. clin. Pharmac.6 (1978) 538–540.Google Scholar
  8. 8.
    Cowen, P. J., and Anderson, I. M., in: Recent advances in the biology of depression. Eds. J. F. W. Deakin and H. Freeman. Royal College of Psychiatrists, special publication, 1986.Google Scholar
  9. 9.
    Cowen, P. J., Geaney, D. P., Schacter, M., Green, A. R., and Elliott, M. J., Desipramine treatment in normal subjects effects on neuroendocrine response to tryptophan and on platelet serotonin (5-HT)-related receptors. Archs gen. Psychiat.43 (1986) 61–67.Google Scholar
  10. 10.
    Cross, A. J., Interactions of [3H]-LSD with serotonin receptors in human brain. Eur. J. Pharmac.82 (1982) 77.Google Scholar
  11. 11.
    Dawbarn, D., Long, S. K., and Pycock, C. J., Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment. Br. J. Pharmac. Chemother.73 (1981) 149–156.Google Scholar
  12. 12.
    Geaney, D. P., Schacter, M., Elliott, J. M., and Grahame-Smith, D. G., Characterization of [3H]-Lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes. Eur. J. Pharmac.97 (1984) 87–93.Google Scholar
  13. 13.
    Glue, P. W., Cowen, P. J., Nutt, D. J., Kolakowska, T., and Grahame-Smith, D. G., The effect of Lithium on 5-HT mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology90 (1986) 398–402.PubMedGoogle Scholar
  14. 14.
    Hefez, A., Oppenheim, B., and Youdim, M. B. H., Human platelet aggregation response to serotonin as an index of efficacy of chlorpromazine, in: Enzymes and Neurotransmitters in Mental Disease, pp. 77–93. Eds E. Usdin, T. L. Sourkes and M. B. H. Youdim. John Wiley, New York 1980.Google Scholar
  15. 15.
    Knox, J. M., Orr, M. W., Allen, R., Gelder, M. G., and Grahame-Smith, D. G., The reliability of 5-hydroxytryptamine reduced platelet aggregation responses in schizophrenic patients with neuroleptic drugs. Br. J. clin. Pharmac.11 (1981) 261–263.Google Scholar
  16. 16.
    Laubscher, A., and Pletscher, A., Shape change and uptake of 5-hydroxytryptamine in human blood platelets: actions of neuropsychotropic drugs. Life Sci.24 (1979) 1833.PubMedGoogle Scholar
  17. 17.
    Laubscher, A., Pletscher, A., and Noll, H., Interaction ofd-LSD with blood platelets of rabbits: shape, change and specific binding. J. Pharmac. exp. Ther.216 (1981) 385.Google Scholar
  18. 18.
    Leysen, J. E., Commeren, W., and de Clerck, F., Demonstration of S2-receptor binding sites in cat platelets using [3H]-ketanserin. Eur. J. Pharmac.88 (1983) 125–130.Google Scholar
  19. 19.
    Mills, D. C. B., and Roberts, G. C. K., Membrane active drugs and the aggregation of human blood platelets. Nature213 (1967) 35–38.Google Scholar
  20. 20.
    Orr, M. W., and Boullin, D. J., The relationship between changes in 5-HT induced platelet aggregation and the clinical state in patients treated with fluphenazine. Br. J. clin. Pharmac.3 (1976) 925–928.Google Scholar
  21. 21.
    Orr, M. W., Knox, J. M., Allen, R., Gelder, M. G., and Grahame-Smith, D. G., The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br. J. clin. Pharmac.11 (1981) 255–259.Google Scholar
  22. 22.
    Peroutka, S. J., and Snyder, S. H., Multiple serotonin receptors differential binding of [3H]-5-hydroxytryptamine, [3H]-lysergic acid diethylamide and [3H]-spiroperidol. Molec. Pharmac.16 (1979) 687–698.Google Scholar
  23. 23.
    Peroutka, S. J., and Snyder, S. H., Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor treatment. Science210 (1980) 88–90.PubMedGoogle Scholar
  24. 24.
    Peters, J. R., and Grahame-Smith, D. G., Human platelet 5-HT receptors: characterisation and functional association. Eur. J. Pharmac.68 (1980) 243.Google Scholar
  25. 25.
    Schacter, M., Geaney, D. P., Grahame-Smith, D. G., Cowen, P., and Elliott, J. M., Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment. Br. J. clin. Pharmac.19 (1985) 453–457.Google Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • D. G. Grahame-Smith
    • 1
  • D. P. Geaney
    • 1
  • M. Schachter
    • 1
  • J. M. Elliott
    • 1
  1. 1.MRC Unit and University Department of Clinical PharmacologyRadcliffe InfirmaryOxford(England)

Personalised recommendations